We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC SUPPORTS TEVA IN DECLARATORY JUDGMENT CASE AGAINST PFIZER
FTC SUPPORTS TEVA IN DECLARATORY JUDGMENT CASE AGAINST PFIZER
April 6, 2004
In a case that could clarify the controversial declaratory judgment provision of last year’s drug patent law, the FTC is urging a federal appeals court to reverse a lower court’s dismissal of generic firm Teva Pharmaceutical’s filing challenging the validity of Pfizer’s patent for the antidepressant Zoloft (sertraline HCl).